Related Experiment Videos
IGF-1 is downregulated in experimental cancer cachexia.
Paola Costelli1, Maurizio Muscaritoli, Maurizio Bossola
1Dipartimento di Medicina e Oncologia Sperimentale, Università di Torino, Turin, Italy. paola.costelli@unito.it
Summary
Cancer cachexia involves muscle wasting linked to hypercatabolism. This study found the Insulin-like Growth Factor-1 (IGF-1) system is downregulated in cachexia, with complex effects on muscle atrophy mechanisms.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cancer cachexia is a debilitating syndrome characterized by progressive skeletal muscle wasting.
- Hypercatabolism and impaired Insulin-like Growth Factor-1 (IGF-1) signaling are implicated in muscle atrophy.
- The AH-130 hepatoma rat model provides a platform to study cachexia-related molecular changes.
Purpose of the Study:
- To investigate the role of the IGF-1 system in cancer cachexia using the AH-130 hepatoma rat model.
- To explore the relationship between IGF-1 signaling, muscle atrophy, and the ubiquitin-proteasome system.
- To evaluate the impact of therapeutic interventions on IGF-1 levels and muscle wasting.
Main Methods:
- Quantification of IGF-1 mRNA expression in gastrocnemius muscle of tumor-bearing rats.
- Measurement of circulating IGF-1 and insulin levels.
- Assessment of IGF-1 receptor and insulin receptor mRNA expression.
- Analysis of ubiquitin-proteasome system components (ubiquitin, atrogin-1, MuRF1) mRNA levels.
- Evaluation of exogenous IGF-1 administration and treatment with pentoxifylline and formoterol.
Main Results:
- IGF-1 mRNA expression significantly decreased in the gastrocnemius of tumor hosts.
- Circulating IGF-1 and hepatic IGF-1 expression were reduced, while IGF-1 and insulin receptor mRNA increased in muscle.
- Muscle wasting correlated with hyperactivation of the ubiquitin-proteasome system, evidenced by increased ubiquitin, atrogin-1, and MuRF1 mRNA.
- Exogenous IGF-1 did not prevent cachexia; therapeutic interventions partially corrected muscle atrophy but did not normalize IGF-1 or atrogin-1 mRNA.
- Combination therapy reduced MuRF1 hyperexpression.
Conclusions:
- The IGF-1 system is demonstrably downregulated in cancer cachexia, though the precise mechanisms require further elucidation.
- A direct correlation between IGF-1/atrogin-1 mRNA levels and muscle atrophy was not consistently observed under these experimental conditions.
- Further research is necessary to fully understand the complex interplay of IGF-1 signaling and muscle wasting in cancer cachexia and to identify effective therapeutic targets.